Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism
Launched by SANWA KAGAKU KENKYUSHO CO., LTD. · Jul 20, 2017
Trial Information
Current as of June 19, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Average serum PTH\>240 pg/mL during 2 weeks at the screening
- • Serum corrected Ca≧8.4 mg/dL at the screening
- • Stable chronic kidney disease patients who undergo hemodialysis or hemodialysis filtration
- Exclusion Criteria:
- • Primary hyperparathyroidism
- • Severe liver disease
- • Severe Cardiac disease
- • History or family history of Long QT syndrome
- • Malignant tumor
- • Uncontrolled diabetes mellitus
- • Uncontrolled hypertension
- • A history of severe drug allergy
About Sanwa Kagaku Kenkyusho Co., Ltd.
Sanwa Kagaku Kenkyusho Co., Ltd. is a leading pharmaceutical and biotechnology company based in Japan, dedicated to the research, development, and commercialization of innovative healthcare solutions. With a strong emphasis on quality and efficacy, the company specializes in a diverse range of therapeutic areas, including oncology, cardiovascular diseases, and infectious diseases. Sanwa Kagaku Kenkyusho is committed to advancing medical science through rigorous clinical trials and collaborative partnerships, striving to improve patient outcomes and contribute to global health advancements. Their focus on cutting-edge research and development underscores their mission to address unmet medical needs and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tokyo, , Japan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials